ID   TREM2_HUMAN             Reviewed;         230 AA.
AC   Q9NZC2; Q8N5H8; Q8WYN6;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   07-APR-2021, entry version 163.
DE   RecName: Full=Triggering receptor expressed on myeloid cells 2;
DE            Short=TREM-2;
DE   AltName: Full=Triggering receptor expressed on monocytes 2;
DE   Flags: Precursor;
GN   Name=TREM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=10799849; DOI=10.4049/jimmunol.164.10.4991;
RA   Bouchon A., Dietrich J., Colonna M.;
RT   "Inflammatory responses can be triggered by TREM-1, a novel receptor
RT   expressed on neutrophils and monocytes.";
RL   J. Immunol. 164:4991-4995(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Begum N.A., Tsukasa S.;
RT   "Identification of a novel variant of triggering receptor, TREM-2V, by mRNA
RT   differential display.";
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, AND INTERACTION WITH TYROBP.
RX   PubMed=11602640; DOI=10.1084/jem.194.8.1111;
RA   Bouchon A., Hernandez-Munain C., Cella M., Colonna M.;
RT   "A DAP12-mediated pathway regulates expression of CC chemokine receptor 7
RT   and maturation of human dendritic cells.";
RL   J. Exp. Med. 194:1111-1122(2001).
RN   [5]
RP   TISSUE SPECIFICITY, INVOLVEMENT IN PLOSL2, AND VARIANTS PLOSL2
RP   44-TRP--THR-230 DEL; 78-TRP--THR-230 DEL; GLY-134 AND ASN-186.
RX   PubMed=12080485; DOI=10.1086/342259;
RA   Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J.,
RA   Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A.,
RA   Tranebjaerg L., Konttinen Y., Peltonen L.;
RT   "Mutations in two genes encoding different subunits of a receptor signaling
RT   complex result in an identical disease phenotype.";
RL   Am. J. Hum. Genet. 71:656-662(2002).
RN   [6]
RP   ERRATUM OF PUBMED:12080485.
RA   Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J.,
RA   Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A.,
RA   Tranebjaerg L., Konttinen Y., Peltonen L.;
RL   Am. J. Hum. Genet. 72:225-225(2003).
RN   [7]
RP   FUNCTION, INVOLVEMENT IN PLOSL2, VARIANT PLOSL2 14-GLU--THR-230 DEL, AND
RP   CHARACTERIZATION OF VARIANT PLOSL2 14-GLU--THR-230 DEL.
RX   PubMed=12925681; DOI=10.1084/jem.20030027;
RA   Paloneva J., Mandelin J., Kiialainen A., Bohling T., Prudlo J., Hakola P.,
RA   Haltia M., Konttinen Y.T., Peltonen L.;
RT   "DAP12/TREM2 deficiency results in impaired osteoclast differentiation and
RT   osteoporotic features.";
RL   J. Exp. Med. 198:669-675(2003).
RN   [8]
RP   INVOLVEMENT IN PLOSL2, AND VARIANTS PLOSL2 33-GLN--THR-230 DEL AND GLY-126.
RX   PubMed=15883308; DOI=10.1212/01.wnl.0000160304.00003.ca;
RA   Kluenemann H.H., Ridha B.H., Magy L., Wherrett J.R., Hemelsoet D.M.,
RA   Keen R.W., De Bleecker J.L., Rossor M.N., Marienhagen J., Klein H.E.,
RA   Peltonen L., Paloneva J.;
RT   "The genetic causes of basal ganglia calcification, dementia, and bone
RT   cysts: DAP12 and TREM2.";
RL   Neurology 64:1502-1507(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=18957693; DOI=10.1126/scisignal.1159665;
RA   Helming L., Tomasello E., Kyriakides T.R., Martinez F.O., Takai T.,
RA   Gordon S., Vivier E.;
RT   "Essential role of DAP12 signaling in macrophage programming into a fusion-
RT   competent state.";
RL   Sci. Signal. 1:RA11-RA11(2008).
RN   [10]
RP   INTERACTION WITH TYROBP.
RX   PubMed=25957402; DOI=10.1074/jbc.m115.645986;
RA   Zhong L., Chen X.F., Zhang Z.L., Wang Z., Shi X.Z., Xu K., Zhang Y.W.,
RA   Xu H., Bu G.;
RT   "DAP12 stabilizes the C-terminal fragment of the triggering receptor
RT   expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-
RT   inflammatory response.";
RL   J. Biol. Chem. 290:15866-15877(2015).
RN   [11]
RP   SUBCELLULAR LOCATION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=24078628; DOI=10.1074/jbc.m113.517540;
RA   Wunderlich P., Glebov K., Kemmerling N., Tien N.T., Neumann H., Walter J.;
RT   "Sequential proteolytic processing of the triggering receptor expressed on
RT   myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-
RT   dependent intramembranous cleavage.";
RL   J. Biol. Chem. 288:33027-33036(2013).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, CHARACTERIZATION OF
RP   VARIANTS CYS-38; HIS-47 AND MET-66, AND MUTAGENESIS OF CYS-36 AND CYS-60.
RX   PubMed=24990881; DOI=10.1126/scitranslmed.3009093;
RA   Kleinberger G., Yamanishi Y., Suarez-Calvet M., Czirr E., Lohmann E.,
RA   Cuyvers E., Struyfs H., Pettkus N., Wenninger-Weinzierl A., Mazaheri F.,
RA   Tahirovic S., Lleo A., Alcolea D., Fortea J., Willem M., Lammich S.,
RA   Molinuevo J.L., Sanchez-Valle R., Antonell A., Ramirez A., Heneka M.T.,
RA   Sleegers K., van der Zee J., Martin J.J., Engelborghs S.,
RA   Demirtas-Tatlidede A., Zetterberg H., Van Broeckhoven C., Gurvit H.,
RA   Wyss-Coray T., Hardy J., Colonna M., Haass C.;
RT   "TREM2 mutations implicated in neurodegeneration impair cell surface
RT   transport and phagocytosis.";
RL   Sci. Transl. Med. 6:243RA86-243RA86(2014).
RN   [13]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS MET-27; VAL-28;
RP   PHE-31; CYS-38; CYS-47; HIS-47; ASN-87; SER-130; GLN-136; TRP-136; LYS-151;
RP   ARG-162 AND ILE-223.
RX   PubMed=27589997; DOI=10.1186/s40478-016-0367-7;
RA   Sirkis D.W., Bonham L.W., Aparicio R.E., Geier E.G., Ramos E.M., Wang Q.,
RA   Karydas A., Miller Z.A., Miller B.L., Coppola G., Yokoyama J.S.;
RT   "Rare TREM2 variants associated with Alzheimer's disease display reduced
RT   cell surface expression.";
RL   Acta Neuropathol. Commun. 4:98-98(2016).
RN   [14]
RP   VARIANTS TYR-157 AND THR-192, AND VARIANTS CYS-183 AND CYS-200 (ISOFORM 2).
RX   PubMed=27067662; DOI=10.1016/j.neurobiolaging.2016.02.023;
RA   Jiang T., Tan L., Chen Q., Tan M.S., Zhou J.S., Zhu X.C., Lu H., Wang H.F.,
RA   Zhang Y.D., Yu J.T.;
RT   "A rare coding variant in TREM2 increases risk for Alzheimer's disease in
RT   Han Chinese.";
RL   Neurobiol. Aging 42:E1-E3(2016).
RN   [15]
RP   FUNCTION, TISSUE SPECIFICITY, CHARACTERIZATION OF VARIANTS CYS-38; HIS-47;
RP   HIS-62; MET-66 AND ASN-87, AND MUTAGENESIS OF LYS-48.
RX   PubMed=27477018; DOI=10.1016/j.neuron.2016.06.015;
RA   Yeh F.L., Wang Y., Tom I., Gonzalez L.C., Sheng M.;
RT   "TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby
RT   Facilitates Uptake of Amyloid-Beta by Microglia.";
RL   Neuron 91:328-340(2016).
RN   [16]
RP   TISSUE SPECIFICITY, AND CHARACTERIZATION OF VARIANTS HIS-47 AND HIS-62.
RX   PubMed=28802038; DOI=10.1016/j.cell.2017.07.023;
RA   Ulland T.K., Song W.M., Huang S.C., Ulrich J.D., Sergushichev A.,
RA   Beatty W.L., Loboda A.A., Zhou Y., Cairns N.J., Kambal A., Loginicheva E.,
RA   Gilfillan S., Cella M., Virgin H.W., Unanue E.R., Wang Y., Artyomov M.N.,
RA   Holtzman D.M., Colonna M.;
RT   "TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.";
RL   Cell 170:649-663(2017).
RN   [17]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND CHARACTERIZATION OF
RP   VARIANT TYR-157.
RX   PubMed=28855300; DOI=10.15252/emmm.201707672;
RA   Schlepckow K., Kleinberger G., Fukumori A., Feederle R.,
RA   Lichtenthaler S.F., Steiner H., Haass C.;
RT   "An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and
RT   affects shedding and phagocytic function.";
RL   EMBO Mol. Med. 9:1356-1365(2017).
RN   [18]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, PROTEOLYTIC PROCESSING, AND
RP   CHARACTERIZATION OF VARIANT TYR-157.
RX   PubMed=28855301; DOI=10.15252/emmm.201707673;
RA   Thornton P., Sevalle J., Deery M.J., Fraser G., Zhou Y., Staahl S.,
RA   Franssen E.H., Dodd R.B., Qamar S., Gomez Perez-Nievas B., Nicol L.S.,
RA   Eketjaell S., Revell J., Jones C., Billinton A., St George-Hyslop P.H.,
RA   Chessell I., Crowther D.C.;
RT   "TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the
RT   Alzheimer's disease-associated H157Y variant.";
RL   EMBO Mol. Med. 9:1366-1378(2017).
RN   [19]
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS CYS-38 AND MET-66, AND
RP   CHARACTERIZATION OF VARIANTS PLOSL2 GLY-126; GLY-134 AND ASN-186.
RX   PubMed=28768830; DOI=10.1091/mbc.e17-06-0423;
RA   Sirkis D.W., Aparicio R.E., Schekman R.;
RT   "Neurodegeneration-associated mutant TREM2 proteins abortively cycle
RT   between the ER and ER-Golgi intermediate compartment.";
RL   Mol. Biol. Cell 28:2723-2733(2017).
RN   [20]
RP   CHARACTERIZATION OF VARIANT HIS-47.
RX   PubMed=30442540; DOI=10.1016/j.jalz.2018.09.006;
RA   Claes C., Van Den Daele J., Boon R., Schouteden S., Colombo A.,
RA   Monasor L.S., Fiers M., Ordovas L., Nami F., Bohrmann B., Tahirovic S.,
RA   De Strooper B., Verfaillie C.M.;
RT   "Human stem cell-derived monocytes and microglia-like cells reveal impaired
RT   amyloid plaque clearance upon heterozygous or homozygous loss of TREM2.";
RL   Alzheimers Dement. 15:453-464(2018).
RN   [21]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=29752066; DOI=10.1016/j.immuni.2018.04.016;
RA   Filipello F., Morini R., Corradini I., Zerbi V., Canzi A., Michalski B.,
RA   Erreni M., Markicevic M., Starvaggi-Cucuzza C., Otero K., Piccio L.,
RA   Cignarella F., Perrucci F., Tamborini M., Genua M., Rajendran L., Menna E.,
RA   Vetrano S., Fahnestock M., Paolicelli R.C., Matteoli M.;
RT   "The Microglial Innate Immune Receptor TREM2 Is Required for Synapse
RT   Elimination and Normal Brain Connectivity.";
RL   Immunity 48:979-991(2018).
RN   [22]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANTS HIS-47 AND HIS-62.
RX   PubMed=29518356; DOI=10.1016/j.neuron.2018.01.031;
RA   Zhao Y., Wu X., Li X., Jiang L.L., Gui X., Liu Y., Sun Y., Zhu B.,
RA   Pina-Crespo J.C., Zhang M., Zhang N., Chen X., Bu G., An Z., Huang T.Y.,
RA   Xu H.;
RT   "TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function.";
RL   Neuron 97:1023-1031(2018).
RN   [23] {ECO:0007744|PDB:5ELI}
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 19-133, DISULFIDE BONDS, SUBUNIT,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF ASN-68; ARG-76 AND ARG-77,
RP   GLYCOSYLATION AT ASN-79, CHARACTERIZATION OF VARIANTS CYS-38; HIS-47;
RP   HIS-62; MET-66; ASN-87 AND LYS-96, AND CHARACTERIZATION OF VARIANT PLOSL2
RP   GLY-126.
RX   PubMed=27995897; DOI=10.7554/elife.20391;
RA   Kober D.L., Alexander-Brett J.M., Karch C.M., Cruchaga C., Colonna M.,
RA   Holtzman M.J., Brett T.J.;
RT   "Neurodegenerative disease mutations in TREM2 reveal a functional surface
RT   and distinct loss-of-function mechanisms.";
RL   Elife 5:E20391-E20391(2016).
RN   [24] {ECO:0007744|PDB:6B8O}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 19-174 IN COMPLEX WITH
RP   PHOSPHATIDYLSERINE, PHOSPHOLIPID-BINDING, DISULFIDE BONDS, FUNCTION,
RP   SUBUNIT, GLYCOSYLATION AT ASN-20 AND ASN-79, CHARACTERIZATION OF VARIANT
RP   HIS-47, AND MUTAGENESIS OF ASN-20.
RX   PubMed=29794134; DOI=10.1074/jbc.ra118.002352;
RA   Sudom A., Talreja S., Danao J., Bragg E., Kegel R., Min X., Richardson J.,
RA   Zhang Z., Sharkov N., Marcora E., Thibault S., Bradley J., Wood S.,
RA   Lim A.C., Chen H., Wang S., Foltz I.N., Sambashivan S., Wang Z.;
RT   "Molecular basis for the loss-of-function effects of the Alzheimer's
RT   disease-associated R47H variant of the immune receptor TREM2.";
RL   J. Biol. Chem. 293:12634-12646(2018).
RN   [25]
RP   VARIANT PLOSL2 33-GLN--THR-230 DEL.
RX   PubMed=12754369; DOI=10.1136/jnnp.74.6.825-a;
RA   Soragna D., Papi L., Ratti M.T., Sestini R., Tupler R., Montalbetti L.;
RT   "An Italian family affected by Nasu-Hakola disease with a novel genetic
RT   mutation in the TREM2 gene.";
RL   J. Neurol. Neurosurg. Psych. 74:825-826(2003).
RN   [26]
RP   VARIANT PLOSL2 33-GLN--THR-230 DEL.
RX   PubMed=23399524; DOI=10.1016/j.jns.2013.01.021;
RA   Bock V., Botturi A., Gaviani P., Lamperti E., Maccagnano C., Piccio L.,
RA   Silvani A., Salmaggi A.;
RT   "Polycystic Lipomembranous Osteodysplasia with Sclerosing
RT   Leukoencephalopathy (PLOSL): a new report of an Italian woman and review of
RT   the literature.";
RL   J. Neurol. Sci. 326:115-119(2013).
RN   [27]
RP   CHARACTERIZATION OF VARIANT PLOSL2 33-GLN--THR-230 DEL, CHARACTERIZATION OF
RP   VARIANTS CYS-38; HIS-47 AND MET-66, AND SUBCELLULAR LOCATION.
RX   PubMed=25615530; DOI=10.1111/tra.12264;
RA   Park J.S., Ji I.J., An H.J., Kang M.J., Kang S.W., Kim D.H., Yoon S.Y.;
RT   "Disease-associated mutations of TREM2 alter the processing of N-linked
RT   oligosaccharides in the Golgi apparatus.";
RL   Traffic 16:510-518(2015).
RN   [28]
RP   VARIANT PLOSL2 33-GLN--THR-230 DEL.
RX   PubMed=29142083; DOI=10.1212/wnl.0000000000004747;
RA   Ghezzi L., Carandini T., Arighi A., Fenoglio C., Arcaro M., De Riz M.,
RA   Pietroboni A.M., Fumagalli G.G., Basilico P., Calvi A., Scarioni M.,
RA   Colombi A., Serpente M., Marotta G., Benti R., Scarpini E., Galimberti D.;
RT   "Evidence of CNS beta-amyloid deposition in Nasu-Hakola disease due to the
RT   TREM2 Q33X mutation.";
RL   Neurology 89:2503-2505(2017).
CC   -!- FUNCTION: Forms a receptor signaling complex with TYROBP which mediates
CC       signaling and cell activation following ligand binding
CC       (PubMed:10799849). Acts as a receptor for amyloid-beta protein 42, a
CC       cleavage product of the amyloid-beta precursor protein APP, and
CC       mediates its uptake and degradation by microglia (PubMed:27477018,
CC       PubMed:29518356). Binding to amyloid-beta 42 mediates microglial
CC       activation, proliferation, migration, apoptosis and expression of pro-
CC       inflammatory cytokines, such as IL6R and CCL3, and the anti-
CC       inflammatory cytokine ARG1 (By similarity). Acts as a receptor for
CC       lipoprotein particles such as LDL, VLDL, and HDL and for
CC       apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4,
CC       and CLU and enhances their uptake in microglia (PubMed:27477018). Binds
CC       phospholipids (preferably anionic lipids) such as phosphatidylserine,
CC       phosphatidylethanolamine, phosphatidylglycerol and sphingomyelin
CC       (PubMed:29794134). Regulates microglial proliferation by acting as an
CC       upstream regulator of the Wnt/beta-catenin signaling cascade (By
CC       similarity). Required for microglial phagocytosis of apoptotic neurons
CC       (PubMed:24990881). Also required for microglial activation and
CC       phagocytosis of myelin debris after neuronal injury and of neuronal
CC       synapses during synapse elimination in the developing brain (By
CC       similarity). Regulates microglial chemotaxis and process outgrowth, and
CC       also the microglial response to oxidative stress and lipopolysaccharide
CC       (By similarity). It suppresses PI3K and NF-kappa-B signaling in
CC       response to lipopolysaccharide; thus promoting phagocytosis,
CC       suppressing pro-inflammatory cytokine and nitric oxide production,
CC       inhibiting apoptosis and increasing expression of IL10 and TGFB (By
CC       similarity). During oxidative stress, it promotes anti-apoptotic NF-
CC       kappa-B signaling and ERK signaling (By similarity). Plays a role in
CC       microglial MTOR activation and metabolism (By similarity). Regulates
CC       age-related changes in microglial numbers (PubMed:29752066). Triggers
CC       activation of the immune responses in macrophages and dendritic cells
CC       (PubMed:10799849). Mediates cytokine-induced formation of
CC       multinucleated giant cells which are formed by the fusion of
CC       macrophages (By similarity). In dendritic cells, it mediates up-
CC       regulation of chemokine receptor CCR7 and dendritic cell maturation and
CC       survival (PubMed:11602640). Involved in the positive regulation of
CC       osteoclast differentiation (PubMed:12925681).
CC       {ECO:0000250|UniProtKB:Q99NH8, ECO:0000269|PubMed:10799849,
CC       ECO:0000269|PubMed:11602640, ECO:0000269|PubMed:12925681,
CC       ECO:0000269|PubMed:24990881, ECO:0000269|PubMed:27477018,
CC       ECO:0000269|PubMed:29518356, ECO:0000269|PubMed:29752066,
CC       ECO:0000269|PubMed:29794134}.
CC   -!- SUBUNIT: Monomer (PubMed:27995897). After ectodomain shedding, the
CC       extracellular domain oligomerizes, which is enhanced and stabilized by
CC       binding of phosphatidylserine (PubMed:29794134). Interacts with
CC       TYROBP/DAP12 (PubMed:11602640, PubMed:25957402). Interaction with
CC       TYROBP is required for stabilization of the TREM2 C-terminal fragment
CC       (TREM2-CTF) which is produced by proteolytic processing
CC       (PubMed:25957402). {ECO:0000269|PubMed:11602640,
CC       ECO:0000269|PubMed:25957402, ECO:0000269|PubMed:27995897,
CC       ECO:0000269|PubMed:29794134}.
CC   -!- INTERACTION:
CC       Q9NZC2; P02649: APOE; NbExp=4; IntAct=EBI-14036387, EBI-1222467;
CC       Q9NZC2; PRO_0000000092 [P05067]: APP; NbExp=4; IntAct=EBI-14036387, EBI-821758;
CC       Q9NZC2; P49768: PSEN1; NbExp=5; IntAct=EBI-14036387, EBI-297277;
CC       Q9NZC2; O43914: TYROBP; NbExp=4; IntAct=EBI-14036387, EBI-2214794;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:24078628, ECO:0000269|PubMed:24990881,
CC       ECO:0000269|PubMed:25615530, ECO:0000269|PubMed:27589997,
CC       ECO:0000269|PubMed:27995897, ECO:0000269|PubMed:28768830,
CC       ECO:0000269|PubMed:28855300, ECO:0000269|PubMed:28855301}; Single-pass
CC       type I membrane protein {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NZC2-1; Sequence=Displayed;
CC       Name=2; Synonyms=TREM-2V;
CC         IsoId=Q9NZC2-2; Sequence=VSP_010792;
CC       Name=3;
CC         IsoId=Q9NZC2-3; Sequence=VSP_010793;
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, specifically in microglia
CC       and in the fusiform gyrus (at protein level) (PubMed:28802038,
CC       PubMed:28855300, PubMed:27477018, PubMed:29752066). Expressed on
CC       macrophages and dendritic cells but not on granulocytes or monocytes
CC       (PubMed:10799849, PubMed:28855301). In the CNS strongest expression
CC       seen in the basal ganglia, corpus callosum, medulla oblongata and
CC       spinal cord (PubMed:12080485). {ECO:0000269|PubMed:10799849,
CC       ECO:0000269|PubMed:12080485, ECO:0000269|PubMed:27477018,
CC       ECO:0000269|PubMed:28802038, ECO:0000269|PubMed:28855300,
CC       ECO:0000269|PubMed:28855301, ECO:0000269|PubMed:29752066}.
CC   -!- PTM: Undergoes ectodomain shedding through proteolytic cleavage by
CC       ADAM10 and ADAM17 to produce a transmembrane segment, the TREM2 C-
CC       terminal fragment (TREM2-CTF), which is subsequently cleaved by gamma-
CC       secretase. {ECO:0000269|PubMed:24078628, ECO:0000269|PubMed:24990881,
CC       ECO:0000269|PubMed:28855300, ECO:0000269|PubMed:28855301}.
CC   -!- DISEASE: Polycystic lipomembranous osteodysplasia with sclerosing
CC       leukoencephalopathy 2 (PLOSL2) [MIM:618193]: An autosomal recessive
CC       disease characterized by presenile frontal dementia with
CC       leukoencephalopathy and basal ganglia calcification. In most cases the
CC       disorder first manifests in early adulthood as pain and swelling in
CC       ankles and feet, followed by bone fractures. Neurologic symptoms
CC       manifest in the fourth decade of life as a frontal lobe syndrome with
CC       loss of judgment, euphoria, and disinhibition. Progressive decline in
CC       other cognitive domains begins to develop at about the same time. The
CC       disorder culminates in a profound dementia and death by age 50 years.
CC       {ECO:0000269|PubMed:12080485, ECO:0000269|PubMed:12754369,
CC       ECO:0000269|PubMed:12925681, ECO:0000269|PubMed:15883308,
CC       ECO:0000269|PubMed:23399524, ECO:0000269|PubMed:25615530,
CC       ECO:0000269|PubMed:27995897, ECO:0000269|PubMed:28768830,
CC       ECO:0000269|PubMed:29142083}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB78736.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF213457; AAF69824.1; -; mRNA.
DR   EMBL; AB062787; BAB78736.1; ALT_INIT; mRNA.
DR   EMBL; BC032362; AAH32362.1; -; mRNA.
DR   CCDS; CCDS4852.1; -. [Q9NZC2-1]
DR   CCDS; CCDS64422.1; -. [Q9NZC2-2]
DR   RefSeq; NP_001258750.1; NM_001271821.1. [Q9NZC2-2]
DR   RefSeq; NP_061838.1; NM_018965.3. [Q9NZC2-1]
DR   PDB; 5ELI; X-ray; 3.10 A; A/B=19-133.
DR   PDB; 5UD7; X-ray; 2.20 A; A/B/C/D/E/F=19-174.
DR   PDB; 5UD8; X-ray; 1.80 A; A/B=19-130.
DR   PDB; 6B8O; X-ray; 2.20 A; A/B/C/D/E/F=19-174.
DR   PDB; 6Z0G; NMR; -; A=161-206.
DR   PDB; 6Z0H; NMR; -; A=161-206.
DR   PDB; 6Z0I; NMR; -; A=161-206.
DR   PDBsum; 5ELI; -.
DR   PDBsum; 5UD7; -.
DR   PDBsum; 5UD8; -.
DR   PDBsum; 6B8O; -.
DR   PDBsum; 6Z0G; -.
DR   PDBsum; 6Z0H; -.
DR   PDBsum; 6Z0I; -.
DR   SMR; Q9NZC2; -.
DR   BioGRID; 119925; 9.
DR   IntAct; Q9NZC2; 6.
DR   STRING; 9606.ENSP00000362205; -.
DR   GlyGen; Q9NZC2; 2 sites.
DR   iPTMnet; Q9NZC2; -.
DR   PhosphoSitePlus; Q9NZC2; -.
DR   BioMuta; TREM2; -.
DR   DMDM; 50401689; -.
DR   jPOST; Q9NZC2; -.
DR   MassIVE; Q9NZC2; -.
DR   PaxDb; Q9NZC2; -.
DR   PeptideAtlas; Q9NZC2; -.
DR   PRIDE; Q9NZC2; -.
DR   ProteomicsDB; 83358; -. [Q9NZC2-1]
DR   ProteomicsDB; 83359; -. [Q9NZC2-2]
DR   ProteomicsDB; 83360; -. [Q9NZC2-3]
DR   Antibodypedia; 2280; 572 antibodies.
DR   DNASU; 54209; -.
DR   Ensembl; ENST00000338469; ENSP00000342651; ENSG00000095970. [Q9NZC2-2]
DR   Ensembl; ENST00000373113; ENSP00000362205; ENSG00000095970. [Q9NZC2-1]
DR   Ensembl; ENST00000373122; ENSP00000362214; ENSG00000095970. [Q9NZC2-3]
DR   GeneID; 54209; -.
DR   KEGG; hsa:54209; -.
DR   UCSC; uc003opy.4; human. [Q9NZC2-1]
DR   CTD; 54209; -.
DR   DisGeNET; 54209; -.
DR   GeneCards; TREM2; -.
DR   GeneReviews; TREM2; -.
DR   HGNC; HGNC:17761; TREM2.
DR   HPA; ENSG00000095970; Tissue enhanced (adipose tissue, brain, lung).
DR   MalaCards; TREM2; -.
DR   MIM; 605086; gene.
DR   MIM; 618193; phenotype.
DR   neXtProt; NX_Q9NZC2; -.
DR   NIAGADS; ENSG00000095970; -.
DR   OpenTargets; ENSG00000095970; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   Orphanet; 275864; Behavioral variant of frontotemporal dementia.
DR   Orphanet; 1020; Early-onset autosomal dominant Alzheimer disease.
DR   Orphanet; 2770; Nasu-Hakola disease.
DR   Orphanet; 238616; NON RARE IN EUROPE: Alzheimer disease.
DR   Orphanet; 100070; Progressive non-fluent aphasia.
DR   Orphanet; 100069; Semantic dementia.
DR   PharmGKB; PA38468; -.
DR   VEuPathDB; HostDB:ENSG00000095970.16; -.
DR   eggNOG; ENOG502S4HV; Eukaryota.
DR   GeneTree; ENSGT00470000042297; -.
DR   HOGENOM; CLU_076120_0_0_1; -.
DR   InParanoid; Q9NZC2; -.
DR   OMA; AWHGQKQ; -.
DR   PhylomeDB; Q9NZC2; -.
DR   TreeFam; TF334441; -.
DR   PathwayCommons; Q9NZC2; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-2172127; DAP12 interactions.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-416700; Other semaphorin interactions.
DR   BioGRID-ORCS; 54209; 4 hits in 978 CRISPR screens.
DR   ChiTaRS; TREM2; human.
DR   GeneWiki; TREM2; -.
DR   GenomeRNAi; 54209; -.
DR   Pharos; Q9NZC2; Tbio.
DR   PRO; PR:Q9NZC2; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q9NZC2; protein.
DR   Bgee; ENSG00000095970; Expressed in substantia nigra and 155 other tissues.
DR   ExpressionAtlas; Q9NZC2; baseline and differential.
DR   Genevisible; Q9NZC2; HS.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0044853; C:plasma membrane raft; IDA:ARUK-UCL.
DR   GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL.
DR   GO; GO:0034186; F:apolipoprotein A-I binding; IPI:ARUK-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:ARUK-UCL.
DR   GO; GO:0008035; F:high-density lipoprotein particle binding; IDA:ARUK-UCL.
DR   GO; GO:0008289; F:lipid binding; TAS:ARUK-UCL.
DR   GO; GO:0001530; F:lipopolysaccharide binding; IEA:Ensembl.
DR   GO; GO:0071813; F:lipoprotein particle binding; IDA:ARUK-UCL.
DR   GO; GO:0070891; F:lipoteichoic acid binding; IEA:Ensembl.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; IDA:ARUK-UCL.
DR   GO; GO:0042834; F:peptidoglycan binding; IEA:Ensembl.
DR   GO; GO:0005543; F:phospholipid binding; IDA:UniProtKB.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; ISS:ARUK-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; ISS:ARUK-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0034189; F:very-low-density lipoprotein particle binding; IDA:ARUK-UCL.
DR   GO; GO:0097242; P:amyloid-beta clearance; IEA:Ensembl.
DR   GO; GO:0043277; P:apoptotic cell clearance; ISS:UniProtKB.
DR   GO; GO:0048143; P:astrocyte activation; ISS:ARUK-UCL.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; ISS:ARUK-UCL.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IEA:Ensembl.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IEA:Ensembl.
DR   GO; GO:0150062; P:complement-mediated synapse pruning; IEA:Ensembl.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:Ensembl.
DR   GO; GO:0097028; P:dendritic cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0032497; P:detection of lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0070392; P:detection of lipoteichoic acid; IEA:Ensembl.
DR   GO; GO:0032499; P:detection of peptidoglycan; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; TAS:ProtInc.
DR   GO; GO:0098657; P:import into cell; ISS:ARUK-UCL.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0001774; P:microglial cell activation; ISS:ARUK-UCL.
DR   GO; GO:0002282; P:microglial cell activation involved in immune response; IEA:Ensembl.
DR   GO; GO:0061518; P:microglial cell proliferation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:1904093; P:negative regulation of autophagic cell death; ISS:ARUK-UCL.
DR   GO; GO:0010507; P:negative regulation of autophagy; ISS:ARUK-UCL.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; IEA:Ensembl.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0150076; P:neuroinflammatory response; IEA:Ensembl.
DR   GO; GO:0030316; P:osteoclast differentiation; IMP:UniProtKB.
DR   GO; GO:0006911; P:phagocytosis, engulfment; IEA:Ensembl.
DR   GO; GO:1900223; P:positive regulation of amyloid-beta clearance; ISS:ARUK-UCL.
DR   GO; GO:0002588; P:positive regulation of antigen processing and presentation of peptide antigen via MHC class II; IDA:BHF-UCL.
DR   GO; GO:2001171; P:positive regulation of ATP biosynthetic process; ISS:ARUK-UCL.
DR   GO; GO:1903082; P:positive regulation of C-C chemokine receptor CCR7 signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:1905291; P:positive regulation of CAMKK-AMPK signaling cascade; ISS:ARUK-UCL.
DR   GO; GO:2000350; P:positive regulation of CD40 signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:ARUK-UCL.
DR   GO; GO:1901076; P:positive regulation of engulfment of apoptotic cell; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; IEA:Ensembl.
DR   GO; GO:1901980; P:positive regulation of inward rectifier potassium channel activity; ISS:ARUK-UCL.
DR   GO; GO:0034241; P:positive regulation of macrophage fusion; ISS:UniProtKB.
DR   GO; GO:1903980; P:positive regulation of microglial cell activation; IMP:UniProtKB.
DR   GO; GO:1904141; P:positive regulation of microglial cell migration; ISS:ARUK-UCL.
DR   GO; GO:0010822; P:positive regulation of mitochondrion organization; ISS:ARUK-UCL.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IMP:UniProtKB.
DR   GO; GO:1901800; P:positive regulation of proteasomal protein catabolic process; ISS:ARUK-UCL.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IMP:UniProtKB.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; ISS:ARUK-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0045088; P:regulation of innate immune response; IEA:Ensembl.
DR   GO; GO:0032675; P:regulation of interleukin-6 production; ISS:ARUK-UCL.
DR   GO; GO:1902531; P:regulation of intracellular signal transduction; ISS:ARUK-UCL.
DR   GO; GO:0071640; P:regulation of macrophage inflammatory protein 1 alpha production; ISS:ARUK-UCL.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0120035; P:regulation of plasma membrane bounded cell projection organization; IGI:ARUK-UCL.
DR   GO; GO:0060075; P:regulation of resting membrane potential; ISS:ARUK-UCL.
DR   GO; GO:0032006; P:regulation of TOR signaling; ISS:ARUK-UCL.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013106; Ig_V-set.
DR   Pfam; PF07686; V-set; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease variant;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Lipid-binding;
KW   Membrane; Neurodegeneration; Receptor; Reference proteome; Secreted;
KW   Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..230
FT                   /note="Triggering receptor expressed on myeloid cells 2"
FT                   /id="PRO_0000014987"
FT   TOPO_DOM        19..174
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        175..195
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        196..230
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          29..112
FT                   /note="Ig-like V-type"
FT   BINDING         67
FT                   /note="Phosphatidylserine"
FT                   /evidence="ECO:0000269|PubMed:29794134,
FT                   ECO:0007744|PDB:6B8O"
FT   BINDING         68
FT                   /note="Phosphatidylserine; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:29794134,
FT                   ECO:0007744|PDB:6B8O"
FT   BINDING         77
FT                   /note="Phosphatidylserine"
FT                   /evidence="ECO:0000269|PubMed:29794134,
FT                   ECO:0007744|PDB:6B8O"
FT   BINDING         88
FT                   /note="Phosphatidylserine"
FT                   /evidence="ECO:0000269|PubMed:29794134,
FT                   ECO:0007744|PDB:6B8O"
FT   SITE            157..158
FT                   /note="Cleavage of ectodomain"
FT                   /evidence="ECO:0000269|PubMed:28855300,
FT                   ECO:0000269|PubMed:28855301"
FT   CARBOHYD        20
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:29794134,
FT                   ECO:0007744|PDB:6B8O"
FT   CARBOHYD        79
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27995897,
FT                   ECO:0000269|PubMed:29794134, ECO:0007744|PDB:5ELI,
FT                   ECO:0007744|PDB:6B8O"
FT   DISULFID        36..110
FT                   /evidence="ECO:0000269|PubMed:27995897,
FT                   ECO:0000269|PubMed:29794134, ECO:0007744|PDB:5ELI,
FT                   ECO:0007744|PDB:5UD7, ECO:0007744|PDB:5UD8,
FT                   ECO:0007744|PDB:6B8O"
FT   DISULFID        51..60
FT                   /evidence="ECO:0000269|PubMed:27995897,
FT                   ECO:0000269|PubMed:29794134, ECO:0007744|PDB:5ELI,
FT                   ECO:0007744|PDB:5UD8, ECO:0007744|PDB:6B8O"
FT   VAR_SEQ         162..230
FT                   /note="SLLEGEIPFPPTSILLLLACIFLIKILAASALWAAAWHGQKPGTHPPSELDC
FT                   GHDPGYQLQTLPGLRDT -> AERHVKEDDGRKSPGEVPPGTSPACILATWPPGLLVLL
FT                   WQETTLPEHCFSWTLEAGTG (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_010792"
FT   VAR_SEQ         162..230
FT                   /note="SLLEGEIPFPPTSILLLLACIFLIKILAASALWAAAWHGQKPGTHPPSELDC
FT                   GHDPGYQLQTLPGLRDT -> PSQGSHLPSCLSKEPLGRRNPLPTHFHPSPPGLHLSHQ
FT                   DSSSQRPLGCSLAWTEARDTSTQ (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010793"
FT   VARIANT         14..230
FT                   /note="Missing (in PLOSL2; results in decreased osteoclast
FT                   differentiation; no TREM2 transcripts can be detected in
FT                   patient cells homozygous for the variant)"
FT                   /evidence="ECO:0000269|PubMed:12925681"
FT                   /id="VAR_081676"
FT   VARIANT         27
FT                   /note="V -> M (found in patients with late onset Alzheimer
FT                   disease; unknown pathological significance; no effect on
FT                   cell membrane localization; dbSNP:rs768745050)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081812"
FT   VARIANT         28
FT                   /note="A -> V (found in patients with late onset Alzheimer
FT                   disease; unknown pathological significance; increases cell
FT                   membrane localization; dbSNP:rs2234252)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081813"
FT   VARIANT         31
FT                   /note="S -> F (found in patients with late onset Alzheimer
FT                   disease; unknown pathological significance; decreases cell
FT                   membrane localization; dbSNP:rs746216516)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081814"
FT   VARIANT         33..230
FT                   /note="Missing (in PLOSL2; no protein detected by Wester
FT                   blot)"
FT                   /evidence="ECO:0000269|PubMed:12754369,
FT                   ECO:0000269|PubMed:15883308, ECO:0000269|PubMed:23399524,
FT                   ECO:0000269|PubMed:25615530, ECO:0000269|PubMed:29142083"
FT                   /id="VAR_081677"
FT   VARIANT         38
FT                   /note="Y -> C (results in defective protein maturation and
FT                   trafficking; loss of proteolytic cleavage by ADAM10 and
FT                   ectodomain shedding; increases protein aggregation;
FT                   decreases cell membrane localization; decreased
FT                   phagocytosis; loss of LDL, CLU and APOE binding; greatly
FT                   decreases LDL and CLU uptake into cells;
FT                   dbSNP:rs797044603)"
FT                   /evidence="ECO:0000269|PubMed:24990881,
FT                   ECO:0000269|PubMed:25615530, ECO:0000269|PubMed:27477018,
FT                   ECO:0000269|PubMed:27589997, ECO:0000269|PubMed:27995897,
FT                   ECO:0000269|PubMed:28768830"
FT                   /id="VAR_081815"
FT   VARIANT         44..230
FT                   /note="Missing (in PLOSL2)"
FT                   /evidence="ECO:0000269|PubMed:12080485"
FT                   /id="VAR_081678"
FT   VARIANT         47
FT                   /note="R -> C (found in patients with late onset Alzheimer
FT                   disease; unknown pathological significance; decreases cell
FT                   membrane localization; dbSNP:rs753325601)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081816"
FT   VARIANT         47
FT                   /note="R -> H (found in patients with late onset Alzheimer
FT                   disease; unknown pathological significance; no effect on
FT                   cell membrane localization; no effect on autophagy in
FT                   microglia; no effect on phagocystosis, including amyloid
FT                   plaque clearance by microglia; reduces ectodomain shedding
FT                   caused by proteolytic cleavage by ADAM10, while also
FT                   reducing the oligomerization of the extracellular domain
FT                   after shedding; decreases binding to and uptake of LDL and
FT                   CLU into cells; decreases binding to APOE, phospholipids
FT                   and oligomeric APP cleavage product beta-amyloid peptide
FT                   42; dbSNP:rs75932628)"
FT                   /evidence="ECO:0000269|PubMed:24990881,
FT                   ECO:0000269|PubMed:25615530, ECO:0000269|PubMed:27477018,
FT                   ECO:0000269|PubMed:27589997, ECO:0000269|PubMed:27995897,
FT                   ECO:0000269|PubMed:28802038, ECO:0000269|PubMed:29518356,
FT                   ECO:0000269|PubMed:29794134, ECO:0000269|PubMed:30442540"
FT                   /id="VAR_081817"
FT   VARIANT         62
FT                   /note="R -> H (does not affect protein structure; no effect
FT                   on cell membrane localization; increases autophagy in
FT                   microglia; decreases LDL, CLU and APOE binding; decreases
FT                   LDL uptake into cells; no effect on CLU uptake into cells;
FT                   decreases the uptake of APP-LDL complex in macrophages;
FT                   decreases binding to oligomeric APP cleavage product beta-
FT                   amyloid peptide 42; dbSNP:rs143332484)"
FT                   /evidence="ECO:0000269|PubMed:27477018,
FT                   ECO:0000269|PubMed:27995897, ECO:0000269|PubMed:28802038,
FT                   ECO:0000269|PubMed:29518356"
FT                   /id="VAR_081818"
FT   VARIANT         66
FT                   /note="T -> M (results in defective protein maturation and
FT                   trafficking; loss of proteolytic cleavage by ADAM10 and
FT                   ectodomain shedding; increases protein aggregation;
FT                   decreases cell membrane localization; decreases
FT                   phagocytosis; loss of LDL, CLU and APOE binding; greatly
FT                   decreases LDL and CLU uptake into cells;
FT                   dbSNP:rs201258663)"
FT                   /evidence="ECO:0000269|PubMed:24990881,
FT                   ECO:0000269|PubMed:25615530, ECO:0000269|PubMed:27477018,
FT                   ECO:0000269|PubMed:27995897, ECO:0000269|PubMed:28768830"
FT                   /id="VAR_081819"
FT   VARIANT         78..230
FT                   /note="Missing (in PLOSL2)"
FT                   /evidence="ECO:0000269|PubMed:12080485"
FT                   /id="VAR_081679"
FT   VARIANT         87
FT                   /note="D -> N (decreases LDL, CLU and APOE binding;
FT                   decreases LDL and CLU uptake into cells; no effect on cell
FT                   membrane localization; dbSNP:rs142232675)"
FT                   /evidence="ECO:0000269|PubMed:27477018,
FT                   ECO:0000269|PubMed:27589997, ECO:0000269|PubMed:27995897"
FT                   /id="VAR_081820"
FT   VARIANT         96
FT                   /note="T -> K (does not change protein structure; changes
FT                   protein stability; increases binding to THP-1 cells;
FT                   dbSNP:rs2234253)"
FT                   /evidence="ECO:0000269|PubMed:27995897"
FT                   /id="VAR_061329"
FT   VARIANT         96
FT                   /note="T -> R (in dbSNP:rs2234253)"
FT                   /id="VAR_061330"
FT   VARIANT         126
FT                   /note="V -> G (in PLOSL2; results in defective protein
FT                   maturation; increases protein aggregation; decreases cell
FT                   membrane localization; dbSNP:rs121908402)"
FT                   /evidence="ECO:0000269|PubMed:15883308,
FT                   ECO:0000269|PubMed:27995897, ECO:0000269|PubMed:28768830"
FT                   /id="VAR_081680"
FT   VARIANT         130
FT                   /note="A -> S (likely benign variant; no effect on protein
FT                   expression and maturation)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081821"
FT   VARIANT         134
FT                   /note="D -> G (in PLOSL2; unknown pathological
FT                   significance; decreased protein level; dbSNP:rs28939079)"
FT                   /evidence="ECO:0000269|PubMed:12080485,
FT                   ECO:0000269|PubMed:28768830"
FT                   /id="VAR_019334"
FT   VARIANT         136
FT                   /note="R -> Q (found in patients with Alzheimer disease;
FT                   unknown pathological significance; slightly decreases cell
FT                   membrane localization; dbSNP:rs149622783)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081822"
FT   VARIANT         136
FT                   /note="R -> W (found in patients with Alzheimer disease;
FT                   unknown pathological significance; decreases cell membrane
FT                   localization; dbSNP:rs772641807)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081823"
FT   VARIANT         151
FT                   /note="E -> K (found in patients with late onset Alzheimer
FT                   disease; unknown pathological significance; decreases cell
FT                   membrane localization; dbSNP:rs79011726)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081824"
FT   VARIANT         157
FT                   /note="H -> Y (may be associated with an increased risk for
FT                   late-onset Alzheimer disease; accelerates ectodomain
FT                   shedding but does not alter the cleavage site; decreases
FT                   cell membrane localization; decreases phagocytosis;
FT                   dbSNP:rs2234255)"
FT                   /evidence="ECO:0000269|PubMed:27067662,
FT                   ECO:0000269|PubMed:28855300, ECO:0000269|PubMed:28855301"
FT                   /id="VAR_033625"
FT   VARIANT         162
FT                   /note="S -> R (no effect on protein expression and
FT                   maturation; dbSNP:rs371702633)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081825"
FT   VARIANT         186
FT                   /note="K -> N (in PLOSL2; unknown pathological
FT                   significance; increased localization at the cell membrane;
FT                   dbSNP:rs28937876)"
FT                   /evidence="ECO:0000269|PubMed:12080485,
FT                   ECO:0000269|PubMed:28768830"
FT                   /id="VAR_019335"
FT   VARIANT         192
FT                   /note="A -> T (in dbSNP:rs150277350)"
FT                   /evidence="ECO:0000269|PubMed:27067662"
FT                   /id="VAR_077696"
FT   VARIANT         211
FT                   /note="L -> P (in dbSNP:rs2234256)"
FT                   /id="VAR_033626"
FT   VARIANT         223
FT                   /note="T -> I (affects protein maturation;
FT                   dbSNP:rs138355759)"
FT                   /evidence="ECO:0000269|PubMed:27589997"
FT                   /id="VAR_081826"
FT   MUTAGEN         20
FT                   /note="N->D: Loss of glycosylation."
FT                   /evidence="ECO:0000269|PubMed:29794134"
FT   MUTAGEN         36
FT                   /note="C->A: Loss of proteolytic cleavage by ADAM10 and
FT                   ectodomain shedding. Decreases protein maturation and cell
FT                   membrane localization."
FT                   /evidence="ECO:0000269|PubMed:24990881"
FT   MUTAGEN         48
FT                   /note="K->M: Loss of LDL, CLU and APOE binding."
FT                   /evidence="ECO:0000269|PubMed:27477018"
FT   MUTAGEN         60
FT                   /note="C->A: Loss of proteolytic cleavage by ADAM10 and
FT                   ectodomain shedding. Decreases protein maturation and cell
FT                   membrane localization."
FT                   /evidence="ECO:0000269|PubMed:24990881"
FT   MUTAGEN         68
FT                   /note="N->K: No effect on cell membrane localization."
FT                   /evidence="ECO:0000269|PubMed:27995897"
FT   MUTAGEN         76
FT                   /note="R->D: Decreases binding to THP-1 cells."
FT                   /evidence="ECO:0000269|PubMed:27995897"
FT   MUTAGEN         77
FT                   /note="R->D: Decreases binding to THP-1 cells."
FT                   /evidence="ECO:0000269|PubMed:27995897"
FT   STRAND          21..27
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   STRAND          32..37
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   TURN            40..45
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   STRAND          48..53
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   TURN            55..57
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   STRAND          60..66
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   HELIX           69..74
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   STRAND          77..79
FT                   /evidence="ECO:0007744|PDB:6B8O"
FT   STRAND          83..87
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   TURN            88..91
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   STRAND          92..97
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   HELIX           102..104
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   STRAND          106..114
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   STRAND          117..129
FT                   /evidence="ECO:0007744|PDB:5UD8"
FT   VARIANT         Q9NZC2-2:183
FT                   /note="S -> C (in dbSNP:rs200820365)"
FT                   /evidence="ECO:0000269|PubMed:27067662"
FT                   /id="VAR_082839"
FT   VARIANT         Q9NZC2-2:200
FT                   /note="W -> C (in dbSNP:rs1391283629)"
FT                   /evidence="ECO:0000269|PubMed:27067662"
FT                   /id="VAR_082840"
SQ   SEQUENCE   230 AA;  25447 MW;  C894AA210F708AF7 CRC64;
     MEPLRLLILL FVTELSGAHN TTVFQGVAGQ SLQVSCPYDS MKHWGRRKAW CRQLGEKGPC
     QRVVSTHNLW LLSFLRRWNG STAITDDTLG GTLTITLRNL QPHDAGLYQC QSLHGSEADT
     LRKVLVEVLA DPLDHRDAGD LWFPGESESF EDAHVEHSIS RSLLEGEIPF PPTSILLLLA
     CIFLIKILAA SALWAAAWHG QKPGTHPPSE LDCGHDPGYQ LQTLPGLRDT
//
